Literature DB >> 26885061

MicroRNA-155 expression as a prognostic factor in patients with gallbladder carcinoma after surgical resection.

Xue-Lin Zhang1, Jun-Hong Chen2, Cheng-Kun Qin3.   

Abstract

BACKGROUND: MicroRNA-155 (miR-155) is over-expressed in both hematopoietic malignancies and solid tumors. In the present study, we investigated the clinical significance of miR-155 in gallbladder carcinoma among Chinese population.
METHODS: Tissue specimens were collected from 133 patients who had undergone surgical resection at Shandong Provincial Hospital, Shandong University between May 2008 and April 2014. We profiled miR- 155 expression in the gallbladder carcinoma tissues and normal gallbladder tissues by qRT-PCR. The Kaplan-Meier method was used to analyze the 5-year survival rate.
RESULTS: The expression levels of miR-155 were significantly higher in gallbladder carcinoma tissues than that in normal gallbladder tissues (P<0.001). High miR-155 expression was significantly associated with TNM stage (P=0.003), lymph node status (P=0.042), liver metastasis (P=0.010), and differentiated degree (P<0.001). We found that gallbladder carcinoma patients with high miR-155 expression level had distinctly shorter overall survival than patients with low miR-155 expression level (P=0.03). Multivariate analysis revealed that miR-155 expression level was independent prognostic factors for overall survival (HR=2.394, 95% CI: 1.568-10.034; P=0.009).
CONCLUSION: High miR-155 expression is a prognostic indicator for poor prognosis of patients with gallbladder carcinoma among Chinese population.

Entities:  

Keywords:  expression; gallbladder carcinoma; microRNA-155; prognostic factor

Year:  2015        PMID: 26885061      PMCID: PMC4723906     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  26 in total

1.  Combined extrahepatic bile duct resection for locally advanced gallbladder carcinoma: does it work?

Authors:  Tsuyoshi Igami; Tomoki Ebata; Yukihiro Yokoyama; Gen Sugawara; Takashi Mizuno; Junpei Yamaguchi; Yoshie Shimoyama; Masato Nagino
Journal:  World J Surg       Date:  2015-07       Impact factor: 3.352

2.  Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.

Authors:  J Khalife; H S Radomska; R Santhanam; X Huang; P Neviani; J Saultz; H Wang; Y-Z Wu; H Alachkar; M Anghelina; A Dorrance; J Curfman; C D Bloomfield; B C Medeiros; D Perrotti; L J Lee; R J Lee; M A Caligiuri; F Pichiorri; C M Croce; R Garzon; M L Guzman; J H Mendler; G Marcucci
Journal:  Leukemia       Date:  2015-05-14       Impact factor: 11.528

Review 3.  RNAi therapeutics and applications of microRNAs in cancer treatment.

Authors:  Keita Uchino; Takahiro Ochiya; Fumitaka Takeshita
Journal:  Jpn J Clin Oncol       Date:  2013-04-16       Impact factor: 3.019

4.  Correlation of Increased Expression of MicroRNA-155 in Bladder Cancer and Prognosis.

Authors:  Hui Wang; Chang-Ping Men
Journal:  Lab Med       Date:  2015

5.  Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.

Authors:  Yongxin Chen; Raymond L Stallings
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

6.  Pathological characteristics of early to advanced gallbladder carcinoma and extrahepatic cholangiocarcinoma.

Authors:  Hiroshi Kijima; Yunyan Wu; Tadashi Yosizawa; Takahiro Suzuki; Yuta Tsugeno; Toshihiro Haga; Hiroko Seino; Satoko Morohashi; Kenichi Hakamada
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-03-03       Impact factor: 7.027

7.  Overexpression of microRNA-155 predicts poor prognosis in glioma patients.

Authors:  Jun Sun; Huachao Shi; Niansheng Lai; Keman Liao; Shuai Zhang; Xiaojie Lu
Journal:  Med Oncol       Date:  2014-03-13       Impact factor: 3.064

8.  MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1.

Authors:  Yang Peng; Wen Dong; Tian-Xin Lin; Guang-Zheng Zhong; Bei Liao; Bo Wang; Peng Gu; Li Huang; Yun Xie; Fu-Ding Lu; Xu Chen; Wei-Bin Xie; Wang He; Shao-Xu Wu; Jian Huang
Journal:  Oncotarget       Date:  2015-06-30

9.  miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.

Authors:  Jana Merhautova; Renata Hezova; Alexandr Poprach; Alena Kovarikova; Lenka Radova; Marek Svoboda; Rostislav Vyzula; Regina Demlova; Ondrej Slaby
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

10.  High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma.

Authors:  Hiroshi Kono; Masafumi Nakamura; Takao Ohtsuka; Yosuke Nagayoshi; Yasuhisa Mori; Shunichi Takahata; Shinichi Aishima; Masao Tanaka
Journal:  Oncol Rep       Date:  2013-05-09       Impact factor: 3.906

View more
  3 in total

1.  Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Authors:  Katrien Van Roosbroeck; Francesca Fanini; Tetsuro Setoyama; Cristina Ivan; Cristian Rodriguez-Aguayo; Enrique Fuentes-Mattei; Lianchun Xiao; Ivan Vannini; Roxana S Redis; Lucilla D'Abundo; Xinna Zhang; Milena S Nicoloso; Simona Rossi; Vianey Gonzalez-Villasana; Rajesha Rupaimoole; Manuela Ferracin; Fortunato Morabito; Antonino Neri; Peter P Ruvolo; Vivian R Ruvolo; Chad V Pecot; Dino Amadori; Lynne Abruzzo; Steliana Calin; Xuemei Wang; M James You; Alessandra Ferrajoli; Robert Orlowski; William Plunkett; Tara M Lichtenberg; Ramana V Davuluri; Ioana Berindan-Neagoe; Massimo Negrini; Ignacio I Wistuba; Hagop M Kantarjian; Anil K Sood; Gabriel Lopez-Berestein; Michael J Keating; Muller Fabbri; George A Calin
Journal:  Clin Cancer Res       Date:  2016-11-30       Impact factor: 12.531

Review 2.  MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers.

Authors:  Yixin Yang; Christopher Alderman; Ayoub Sehlaoui; Yuan Xiao; Wei Wang
Journal:  Can J Gastroenterol Hepatol       Date:  2018-06-26

3.  Overexpression of miR-1283 Inhibits Cell Proliferation and Invasion of Glioma Cells by Targeting ATF4.

Authors:  Hao Chen; Yi Zhang; Hai Su; Hui Shi; Qijiang Xiong; Zulu Su
Journal:  Oncol Res       Date:  2018-05-01       Impact factor: 5.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.